9-(4-fluorophenyl)-6-ethyl-2-(trifluoromethyl)purine | 658707-99-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 9-(4-fluorophenyl)-6-ethyl-2-(trifluoromethyl)purine
• 英文别名: 6-Ethyl-9-(4-fluorophenyl)-2-(trifluoromethyl)purine
• CAS: 658707-99-4
• 化学式: C₁₄H₁₀F₄N₄
• 分子量: 310.254
• InChiKey: DVMHSSORENHBRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• [EN] PHOSPHODIESTERASE 4 INHIBITORS<br/>[FR] INHIBITEURS DE LA PHOSPHODIESTERASE 4 (PDE4)
  申请人：MEMORY PHARM CORP

  公开号：WO2004014911A1

  公开（公告）日：2004-02-19

  PDE4 inhibition is achieved by novel compounds of the Formula (I), wherein R1 and R2 are as defined herein.

  PDE4抑制是通过式(I)的新化合物实现的，其中R1和R2如本文所定义。
• Phosphodiesterase 4 inhibitors
  申请人：MEMORY PHARMACEUTICALS CORP.

  公开号：US20040102460A1

  公开（公告）日：2004-05-27

  PDE4 inhibition is achieved by novel compounds of the Formula I: 1 wherein R 1 and R 2 are as defined herein.

  PDE4抑制是通过公式I的新化合物实现的：其中R1和R2如下所定义。
• PHOSPHODIESTERASE 4 INHIBITORS
  申请人：HOPPER Allen T.

  公开号：US20090325982A1

  公开（公告）日：2009-12-31

  PDE 4 inhibition is achieved by novel compounds of the Formula I: wherein R 1 and R 2 are as defined herein.

  PDE4抑制是通过公式I中的新化合物实现的：其中R1和R2的定义如下。
• US7335654B2
  申请人：——

  公开号：US7335654B2

  公开（公告）日：2008-02-26
• [EN] COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] COMBINAISONS D'INHIBITEURS DE PDE4 ET D'ANTIPSYCHOTIQUES POUR LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
  申请人：MEMORY PHARM CORP

  公开号：WO2009067607A2

  公开（公告）日：2009-05-28

  The invention relates to methods and compositions for treating a psychotic disorder or condition, associated with cognitive impairment. The pharmaceutical composition comprises: (a) an amount of an antipsychotic agent and (b) an amount of a PDE4 inhibitor compound, wherein the amounts of (a) and (b) are together effective in treating the cognitive impairment or psychotic disorder such as schizophrenia. The method of treatment comprises administering to a patient (a) an amount of a antipsychotic agent and (b) an amount of a PDE4 inhibitor compound, wherein the amounts of (a) and (b) are together effective in treating the psychotic disorder such as schizophrenia.